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Gynecological cancer
Results of curative treatment in cervical carcinoma
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We analyze the characteristics and results of the treatment of 206 patients with a diagnosis of carcinoma of cervix treated
between 2006 and 2012 with curative radiotherapy.
General characteristics. Median age: 54 years (23–90). Histology: squamous cell carcinoma 158 (77%), adenosquamous 34 (17%).
Stages. Stage Ib and II 169 patients, III 24 and IV 8 patients. Only 53 patients have nodal involvement (26%). Concomitant
chemotherapy to external radiotherapy was administrated to 132 patients (64%), utero-vaginal brachytherapy was associated
to external radiation in 190 cases (92%). Previously to brachytherapy, clinical response of external radiation and chemotherapy
was assessed. Total response was in 33% of the cases, partial response >75% in 47% of the cases and partial response >50% was
13%.
Results. With a median follow up of 33 months (6–123), 185 patients (90%) obtained local control of the disease. Nodal recurrence
is evidenced in 9 (4%) and metastases in 23 (11%) The most common location is in the lungs (8/23). -Loco-regional relapse-free
survival is 84% at 2 years and 81% at 5 and 10 years. -The nodal relapse-free survival is 85% at 2 years and 80% at 5 and 10 years.
-Metastasis-free survival is 82% at 2 years and 78% at 5 and 10 years. -The disease-free survival at 2 years is 82% and at 5 and 10
years of 81%. -Overall survival at 2 years is 88% and at 5 and 10 years 83%. No evidence of signiﬁcant urinary or gastrointestinal
toxicity in both acute and late effects was observed.
Conclusion. The association of chemotherapy to external radiotherapy and uterovaginal brachytherapy has evidenced to be an
effective treatment for patients with cervical carcinoma.
http://dx.doi.org/10.1016/j.rpor.2013.03.225
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Introduction. Adenosarcomas of the uterus (ADS) are relatively rare uterine sarcomas, with a very low incidence; nowadays there
is little information about ADS behaviour, histological features, prognosis factors and treatment. We retrospectively analysed
the outcome of 12 patients diagnosed and treated at our centre.
Material and methods. From 1979 to 2012 the records and pathology of 12 patients diagnosed with ADS and treated at our centre
were reviewed. Total abdominal hysterectomy and bilateral salpingo-oophorectomy was considered as the standard surgical
procedure for all the patients and only four lymphadenectomy were made. External beam radiotherapy (EBRT) was administered
in three patients as adjuvant therapy and four patients received brachytherapy. The Kaplan- Meier actuarial method was used
to analyse the overall survival (OS) and disease-free survival (DFS).
Results. The median follow up of the patients was 50 months and it ranged between 3 and 190 months. After surgery all the
12 patients had limited uterus disease. Five patients had a relapse (41%), two cases were limited to the pelvis, in two patients
metastatic disease was associated to local relapse and one case of exclusively metastases. The irradiated patients mean DFS
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